Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.30 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.30 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.30 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8439081 | 0.83 | P2RX4 (0.33) | ALDH1A1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL23515745 | 0.79 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL8902047 | 0.75 | ALDH1A1 (0.35) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL22644257 | 0.75 | CHRM2 (0.30) | ALDH1A1 | |
| SCHEMBL24760 | 0.71 | — | — | |
| SCHEMBL6523333 | 0.71 | ALDH1A1 (0.50) | ALDH1A1TSHRNFKB1THPOHSD17B10 | |
| SCHEMBL1869393 | 0.71 | CA1 (0.38) | — | |
| SCHEMBL10871210 | 0.69 | P2RX4 (0.33) | ALDH1A1P2RX1P2RX3P2RX4P2RX7 | |
| SCHEMBL21141115 | 0.69 | POLB (0.33) | — | |
| SCHEMBL21169575 | 0.69 | CHRNB2 (0.31) | ALDH1A1TSHRCHRNB2CHRNB4CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226130-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | Atrin Pharmaceuticals LLC (US) | 2017-08-10 | — | — | US | disclosed |
| US-9663535-B2 | Ataxia telengiectasia and Rad3-related (ATR) protein kinase inhibitors | Atrin Pharmaceuticals LLC (US) | 2017-05-30 | — | — | US | disclosed |
| US-20160102104-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | Atrin Pharmaceuticals LLC (US) | 2016-04-14 | — | — | US | disclosed |
| US-7858635-B2 | Spiro compounds as modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-28 | — | — | US | disclosed |
| US-7462325-B2 | Luminescent polymer particles | NOMADICS, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20080015179-A1 | Modulators of muscarinic receptors | VERTEX PHARMACEUTICALS INCORPORATED | 2008-01-17 | — | — | US | disclosed |
| WO-2003048226-A9 | LUMINESCENT POLYMER PARTICLES | NOMADICS INC (US) | 2004-04-22 | — | — | WO | disclosed |
| US-20030134959-A1 | For immobilizing a biological, biochemical, or chemical molecule onto the particle; polymer contains a bicyclic ring system comprising an iptycene moiety and preferably anionic or cationic groups. | FLIR DETECTION, INC. | 2003-07-17 | — | — | US | disclosed |
| WO-2003048226-A2 | LUMINESCENT POLYMER PARTICLES | NOMADICS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| US-4349526-A | TRI-SUBSTITUTED PHENYLUREAS AS SOLVENT IN ANTHRAQUINONE PROCESS | DEGUSSA AKTIENGESELLSCHAFT (DE) | 1982-09-14 | — | — | US | disclosed |
| US-4090024-A | Process for the production of skatylhydantoin | DEUTSCHE GOLD- UND SILBER-SCHEIDEANSTALT VORMALS ROESSLER (DT) | 1978-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226130-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | CHEK2, ATR, CHEK1 | ALDH1A1 4240/4885TSHR 884/4885MEN1 431/4885 |
| US-20160102104-A1 | Ataxia Telengiectasia And Rad3-Related (ATR) Protein Kinase Inhibitors | ATR, CHEK1, CHEK2 | ALDH1A1 4356/4885TSHR 986/4885MEN1 2288/4885 |
| US-20080015179-A1 | Modulators of muscarinic receptors | CHRM3, CHRM5, CHRM2 | ALDH1A1 2356/4885TSHR 131/4885MEN1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.